Reuters: EU regulator backs revoking Amgen's right to sell rare-disease drug | Source Library

ArticleGeneral published source

Source type: Article
Access type: Publisher
Publisher: Reuters
Date: 2026-06-26
Added: 2026-06-30

Trust profile

VV Source Trust Matrix v1.0

VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.

General published source

Publisher type: General media
Bias profile: Elevated

This source is strongest for consumer context and regulatory status and weaker for safety and trial discovery.

VV Source Fit Score 1.0

Fit by use case

Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.

Frameworks ->

Regulatory status: 54/100; Weak Support
Clinical outcomes: 54/100; Weak Support
Mechanism: 54/100; Weak Support
Safety: 54/100; Weak Support
Consumer context: 67/100; Context Source
Trial discovery: 54/100; Weak Support

Best used for

Context
Public narrative

Weak for

Clinical claims
Safety conclusions
Regulatory status

Used in Viral Vitalism

Backgroundbrief1 reference

EMA Recommended Revoking Tavneos Authorization After Data Integrity and Liver Safety Concerns

Roles: Background

Show section-level references

EMA recommended revoking Tavneos' EU marketing authorization after finding that the main study supporting approval was unreliable and that available evidence did not sufficiently confirm benefit relative to risk.

Backgroundtimeline1 reference

EMA recommends Tavneos authorization revocation

Roles: Background

Show section-level references

EMA's reported recommendation put Tavneos into a benefit-risk, liver-safety, and clinical-trial-integrity review lane while final EU action remained pending.

Related studies

No structured study record is currently attached to this source.

Related sources

GovernmentU.S. health regulator

FDA: Drug Trials Snapshot for Tavneos

Background regulatory context for the original U.S. approval and studied population.

Trust score: 94
Publisher: U.S. Food and Drug Administration
Access: Official
Usage: 2 connections

Inspect source ->

GovernmentU.S. health regulator

FDA: Draft Guidance to Help Accelerate Cell and Gene Therapies

Canonicalized from rapid brief fda-rare-disease-gene-therapy-flexibility.

Trust score: 94
Publisher: U.S. Food and Drug Administration
Access: Official
Usage: 1 connection

Inspect source ->

GovernmentU.S. health regulator

FDA: Leveraging Prior Knowledge in Gene Therapy Products Incorporating Genome Editing

Canonicalized from rapid brief fda-rare-disease-gene-therapy-flexibility.

Trust score: 94
Publisher: U.S. Food and Drug Administration
Access: Official
Usage: 1 connection

Inspect source ->

GovernmentU.S. health regulator

FDA: First Gene Therapies to Treat Patients with Sickle Cell Disease

Canonicalized from rapid brief daniel-cressy-sickle-cell-gene-therapy-louisiana.

Trust score: 94
Publisher: U.S. Food and Drug Administration
Access: Official
Usage: 2 connections

Inspect source ->

ArticleGeneral published source

Regenxbio: Alignment with FDA on path forward for Navsunli BLA resubmission

Canonicalized from rapid brief regenxbio-navsunli-rgx-121-fda-accelerated-approval-path.

Trust score: 60
Publisher: Regenxbio
Access: Publisher
Usage: 1 connection

Inspect source ->

ArticleGeneral published source

Reuters: FDA reverses course on Regenxbio rare-disease gene therapy

Canonicalized from rapid brief regenxbio-navsunli-rgx-121-fda-accelerated-approval-path.

Trust score: 60
Publisher: Reuters
Access: Publisher
Usage: 2 connections

Inspect source ->

Topic tags

medicinerare-diseaseimmunologydrug-safetyregulatory-watchclinical-trial-integritytavneosavacopananca-associated-vasculitis